What is Leerink Partnrs’ Estimate for ORKA FY2024 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Oruka Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($1.56) per share for the year, down from their previous forecast of ($1.33). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at ($1.99) EPS.

A number of other research firms have also recently weighed in on ORKA. Leerink Partners started coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Thursday, October 31st. TD Cowen initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a “buy” rating on the stock. Finally, Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Price Performance

ORKA opened at $22.30 on Monday. The stock has a market cap of $26.98 million, a price-to-earnings ratio of -3.48 and a beta of 0.87. The business has a 50 day simple moving average of $26.62. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new stake in Oruka Therapeutics during the 3rd quarter worth about $343,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $2,013,000. The Manufacturers Life Insurance Company purchased a new position in shares of Oruka Therapeutics during the 3rd quarter worth $1,037,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $11,699,000. Finally, Janus Henderson Group PLC purchased a new position in Oruka Therapeutics during the third quarter worth about $5,840,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.